Prepare the ringer lactate Solution for injection Principal Procedure Category Storage Standard Ingredients /composition Observation consist of working formula and official formula
Reading File
Searching the Web
Ringer's Lactate Solution for injection preparation official formula pharmacopoeia
Finding Sources
Reading Web Page
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3d…
Reading File
Reading File
Searching the Web
Ringer lactate solution IP BP preparation procedure sterilization working formula observation table pharmacy
I now have comprehensive information from authoritative sources (USP, IP/BP, DailyMed, StatPearls, and major surgical textbooks). Let me compose the full monograph.
Ringer's Lactate Solution for Injection
(Compound Sodium Lactate Injection / Hartmann's Solution)
1. CATEGORY
- Type: Sterile, isotonic, balanced crystalloid parenteral solution
- Pharmacological Class: Electrolyte replenisher / Plasma volume expander / Alkalinizing agent
- Pharmacopoeia Classification: Large Volume Parenteral (LVP) - Listed in IP (Indian Pharmacopoeia), BP (British Pharmacopoeia), USP (United States Pharmacopoeia), and Eur.Ph. (European Pharmacopoeia)
- Schedule / Route: Rx only; Intravenous (IV) infusion
2. PRINCIPAL (Purpose & Background)
Ringer's Lactate Solution (RL) is an isotonic crystalloid fluid devised to closely mimic the ionic composition of human blood plasma. It was originally developed in the 1880s by Sydney Ringer (who demonstrated the necessity of calcium and potassium for cardiac contractions) and later modified in 1932 by pediatrician Alexis Hartmann, who added sodium lactate to create an alkalinizing solution for acidotic pediatric patients - hence the alternate name Hartmann's Solution.
The sodium lactate component serves as an indirect bicarbonate precursor: lactate is metabolized to bicarbonate in the liver via the citric acid cycle, producing a mild alkalinizing effect without the abrupt pH shift caused by sodium bicarbonate. This property makes RL particularly useful in treating metabolic acidosis and hypovolemia.
Key properties:
- Osmolarity: ~273 mOsmol/L (mildly hypotonic relative to plasma; physiologic range 280-310)
- pH: 6.0 - 7.5 (adjusted with HCl or NaOH; typically ~6.5)
- Caloric content: ~9 kcal/L
- Tonicity: Isotonic / slightly hypotonic
Clinical Uses:
- Fluid and electrolyte resuscitation (hypovolemia, hemorrhage, burns, sepsis)
- Pre- and post-operative IV fluid maintenance
- Treatment of mild-to-moderate metabolic acidosis
- Irrigation of eyes after chemical burns
- Adjunct in acute pancreatitis resuscitation (preferred over normal saline due to anti-inflammatory effects)
3. INGREDIENTS / COMPOSITION (Official Formula)
3A. Official Formula (USP / IP / BP) - Per 1000 mL
| Ingredient | Chemical Name | Molecular Formula | Mol. Wt. | Amount (g/L) |
|---|---|---|---|---|
| Sodium Chloride USP/IP | Sodium Chloride | NaCl | 58.44 | 6.0 g |
| Sodium Lactate | Monosodium L-Lactate | CH₃CH(OH)COONa | 112.06 | 3.1 g |
| Potassium Chloride USP/IP | Potassium Chloride | KCl | 74.55 | 0.30 g |
| Calcium Chloride USP/IP | Calcium Chloride Dihydrate | CaCl₂·2H₂O | 147.02 | 0.20 g |
| Water for Injection | - | H₂O | 18.02 | q.s. to 1000 mL |
pH adjusted with Hydrochloric Acid NF or Sodium Hydroxide NF as needed.
3B. Ionic Concentration (per litre)
| Ion | Concentration (mEq/L) | Concentration (mmol/L) |
|---|---|---|
| Sodium (Na⁺) | 130 | 130 |
| Potassium (K⁺) | 4 | 4 |
| Calcium (Ca²⁺) | 3 (2-3) | 1.5 |
| Chloride (Cl⁻) | 110 (109-111) | 109 |
| Lactate (CH₃CH(OH)COO⁻) | 28 | 28 |
4. PROCEDURE OF PREPARATION
Equipment Required
- Stainless steel mixing vessel (Grade 316 SS)
- Pyrogen-free / depyrogenated glass bottles or IV bags
- Membrane filter (0.22 µm sterilizing grade)
- Autoclave / Terminal steam sterilizer
- pH meter, analytical balance
- Laminar air flow (LAF) unit / clean room (Class B/C area)
Step-by-Step Preparation
Step 1 - Preparation of Water for Injection (WFI)
- Prepare freshly distilled, pyrogen-free Water for Injection (WFI) meeting IP/USP/BP standards.
- Use approximately 80% of the final volume as the dissolving medium.
Step 2 - Dissolution of Salts (in sequence)
- Weigh accurately per batch formula (see working formula below).
- In the mixing vessel, add Sodium Chloride to the WFI and stir to dissolve completely.
- Add Sodium Lactate solution (60% w/v stock solution, equivalent to 3.1 g anhydrous sodium lactate per litre).
- Add Potassium Chloride and stir until dissolved.
- Add Calcium Chloride Dihydrate last (to minimize precipitation risk with lactate).
Note: Calcium chloride must always be added last and with gentle, continuous stirring to prevent the formation of calcium lactate precipitate.
Step 3 - pH Adjustment
- Check pH using a calibrated pH meter.
- Adjust to pH 6.0-7.5 (target ~6.5) with:
- Dilute Hydrochloric Acid NF (to lower pH) or
- Sodium Hydroxide NF (to raise pH)
Step 4 - Volume Adjustment
- Make up to the final volume with WFI (q.s. to 100%, e.g., 1000 mL per litre batch).
Step 5 - Clarity Check (Pre-filtration)
- Inspect solution under strong light for particulate matter, turbidity, or discoloration.
- Discard batch if not clear and colorless.
Step 6 - Filtration
- Filter the solution through a 0.22 µm membrane filter (sterilizing-grade) using positive nitrogen pressure (aseptic technique) into pre-sterilized filling vessels.
Step 7 - Filling
- Fill into sterile, pyrogen-free glass bottles (Type I or Type II) or multilayered polymer IV bags (EXCEL/VIAFLEX-type).
- Seal with rubber stoppers and aluminum crimp seals (for glass bottles) or heat-seal for bags.
Step 8 - Sterilization (Terminal Sterilization)
- Subject filled, sealed containers to moist heat sterilization (autoclaving) in a validated autoclave:
- Temperature: 121°C
- Pressure: 15 psi (103 kPa)
- Time: 15-20 minutes (overkill conditions, F₀ ≥ 8 min, per Eur.Ph.)
- This is the preferred method and complies with pharmacopoeia requirements.
Alternative (Aseptic Processing): If terminal sterilization is not feasible, the solution may be filtered through a 0.22 µm sterilizing filter under aseptic conditions and filled into pre-sterilized containers in a Grade A (Class 100) laminar airflow environment.
Step 9 - Post-sterilization Inspection
- Inspect each container for:
- Clarity and absence of particulate matter
- Container integrity (no leaks, cracks)
- Label accuracy
5. OBSERVATIONS
5A. Working Formula (Batch Size: 1000 mL)
| Ingredient | Quantity per 1000 mL | Purpose |
|---|---|---|
| Sodium Chloride IP/USP | 6.0 g | Provides Na⁺ and Cl⁻ ions; tonicity agent |
| Sodium Lactate solution (60% w/v) | 5.16 mL (equiv. to 3.1 g anhydrous) | Provides lactate; alkalinizing precursor |
| Potassium Chloride IP/USP | 0.30 g | Provides K⁺ ions; electrolyte replacement |
| Calcium Chloride Dihydrate IP/USP | 0.20 g | Provides Ca²⁺ ions; electrolyte replacement |
| Hydrochloric Acid NF | q.s. | pH adjustment to 6.0-7.5 |
| Water for Injection | q.s. to 1000 mL | Vehicle / solvent |
5B. Official Formula Comparison (Different Pharmacopoeias)
| Parameter | USP (Lactated Ringer's Inj.) | IP / BP (Compound Sodium Lactate Inj.) | Eur.Ph. |
|---|---|---|---|
| NaCl | 6.0 g/L | 6.0 g/L | 6.0 g/L |
| Sodium Lactate | 3.1 g/L | 3.1 g/L | 3.1 g/L |
| KCl | 0.30 g/L | 0.40 g/L* | 0.30 g/L |
| CaCl₂·2H₂O | 0.20 g/L | 0.27 g/L* | 0.20 g/L |
| pH | 6.0-7.5 | 5.0-7.0 | 5.0-7.0 |
| Osmolarity | 273 mOsmol/L | ~273 mOsmol/L | ~275 mOsmol/L |
* Slight variations exist between manufacturers and pharmacopoeias; the term "Ringer's Lactate" should not be equated with a single precise formulation across all brands.
5C. Observation Table (Quality Control Checks)
| Test | Expected Result / Specification |
|---|---|
| Description | Clear, colorless aqueous solution; free from particles |
| pH | 6.0 - 7.5 (USP); 5.0 - 7.0 (IP/BP) |
| Osmolarity | 273 - 275 mOsmol/L (calculated) |
| Sodium content | 130 mEq/L (126-136 mEq/L acceptable range) |
| Potassium content | 4 mEq/L |
| Calcium content | 2-3 mEq/L (1.5 mmol/L) |
| Chloride content | 109-111 mEq/L |
| Lactate content | 28-29 mEq/L |
| Sterility | Passes USP/IP Sterility Test (no microbial growth) |
| Pyrogen / Bacterial Endotoxin | Passes LAL test; < 0.25 EU/mL |
| Particulate matter | Passes USP <788> / IP Particulate Matter test |
| Container integrity | No leaks on firm compression of container |
6. STORAGE
| Condition | Specification |
|---|---|
| Temperature | Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) - USP Controlled Room Temperature |
| Heat exposure | Minimize exposure to heat; avoid excessive heat |
| Freezing | Protect from freezing |
| Light | Store in overwrap / secondary packaging until ready for use |
| Post-opening | Single-use only; discard any unused portion |
| After additive mixing | Do not store solutions with added medications; use immediately |
7. STANDARD (Quality / Regulatory Standards)
| Standard | Details |
|---|---|
| USP | Lactated Ringer's Injection, USP - official monograph |
| IP (Indian Pharmacopoeia) | Compound Sodium Lactate Injection IP |
| BP (British Pharmacopoeia) | Compound Sodium Lactate Intravenous Infusion BP |
| Eur.Ph. | Sodium Lactate Solution, Compound (Ringer-Lactate Solution) |
| Sterilization standard | Terminal moist heat sterilization, 121°C/15 min, F₀ ≥ 8 min (Eur.Ph. overkill conditions) |
| Container standard | Glass: Type I or Type II (USP/IP); Polymer: multilayered EVA/PP film - no PVC, no DEHP, no natural rubber latex (per current standards) |
| Endotoxin limit | < 0.25 EU/mL (LAL test, USP <85>) |
| Particulate matter | USP <788> / IP 2.9.19 |
| Labelling | Must state: "Not for use in lactic acidosis"; "Single-dose container"; "For IV use only" |
8. PRECAUTIONS / CONTRAINDICATIONS (Pharmacopoeia-Aligned)
- Contraindicated in lactic acidosis (label warning: "NOT FOR USE IN THE TREATMENT OF LACTIC ACIDOSIS")
- Avoid in severe hepatic failure (lactate cannot be metabolized)
- Use with caution in congestive heart failure, renal impairment, and hyperkalemia (due to K⁺ content)
- Do not administer simultaneously with blood through the same line (calcium can chelate citrate anticoagulant in stored blood)
- Some additives may be incompatible - consult pharmacist before mixing; mix thoroughly and do not store after addition
- Do not use in series connection (risk of air embolism)
References:
- DailyMed - Lactated Ringer's Injection USP (B. Braun), official USP labeling
- Sabiston Textbook of Surgery, 21e - Fluids section, p. 3344
- Miller's Anesthesia, 10e - Balanced Crystalloid Solutions, p. 6354
- StatPearls - Crystalloid Solutions in IV Fluid Therapy
- Wikipedia - Ringer's Lactate Solution (composition reference)
- MacoPharma Public Assessment Report, Eur.Ph. monograph compliance, 2007
This is a shared conversation. Sign in to Orris to start your own chat.